drugset / Trial / NCT00781781
Alemtuzumab Use (MabCampath®) in Hematopoietic Transplant of Unrelated Donor With Reduced Intensity Conditioning
Phase 2
Terminated
34 enrolled
CABYC
Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea · collab
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to analyze the results of incidence and severity of acute and chronic GVHD, (see addendum II) and of disease free survival with Alemtuzumab use (MabCampath®) in haematopoietic transplant of unrelated donor with reduced intensity conditioning.
Timeline
- Start
- 2008-07
- Primary completion
- 2008-08
- Completion
- 2011-12
Outcome
Outcome not reported
Stopped (Enrollment): “Inability to recruit the number of patients established in the study protocol (34 of 40)”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Alemtuzumab | Monoclonal antibody | 10 mg | Intravenous |
| Subject | Alemtuzumab | Monoclonal antibody | 20 mg | Intravenous |